EGFR and conjunctivitis: However, a significant correlation was found with the use of EGFR inhibitors, indicating a higher likelihood of experiencing conjunctivitis and scleritis in 18.41% of patients (37/201) (p = 0.008, odds ratio = 5.65, 95% CI = 1.76-18.19).